Bluejay director granted 100K options tied to FDA

Q: What is the exercise price of the new BJDX stock options granted to Wurth Douglas Clark?

The stock options granted to Wurth Douglas Clark have an exercise price of $2.075 per share. They are described as out-of-the-money options that become exercisable only after vesting and upon specified FDA clearance or approval conditions.

Q: When do Wurth Douglas Clark’s BJDX options vest and become exercisable?

The options vest and become exercisable on the first anniversary of the grant date. However, they are additionally conditioned on the U.S. FDA granting clearance or approval of Bluejay’s Symphony IL-6 point-of-care testing device.

Q: What regulatory condition affects exercisability of Wurth Douglas Clark’s BJDX options?

The options are not exercisable unless and until the U.S. Food and Drug Administration grants clearance or approval of Bluejay Diagnostics’ Symphony IL-6 point-of-care testing device, adding a regulatory milestone condition beyond standard vesting.

Q: When do the BJDX stock options granted to Wurth Douglas Clark expire?

The stock options granted to Wurth Douglas Clark expire on August 17, 2031. If vesting and the FDA clearance or approval condition are not satisfied before that date, any unexercised portion of the option would remain unexercisable through expiration.

Bluejay Diagnostics, Inc. (BJDX) reported that director Wurth Douglas Clark received a grant of stock options for 100,000 shares of common stock.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Bluejay Diagnostics, Inc. (BJDX) reported that director Wurth Douglas Clark received a grant of stock options for 100,000 shares of common stock. The options have an exercise price of $2.075 per share, expire on August 17, 2031, and are currently out-of-the-money. They vest on the first anniversary of the grant date and cannot be exercised unless and until the U.S. Food and Drug Administration grants clearance or approval of Bluejay’s Symphony IL-6 point-of-care testing device.

Insider Trade Summary

Grant/Award: 100,000 shares

Grant/Award 1 txn

Insider Wurth Douglas Clark

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) ^F1	100,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 100,000 contracts (Direct)

Footnotes (1)

F1. Represents out-of-the-money stock options that vest and become exercisable for $2.075 per share on the first anniversary of the grant date, provided, however, that the options shall not be exercisable unless and until the U.S. Food and Drug Administration shall have granted clearance or approval of the issuer's Symphony IL-6 point-of-care testing device.

Key Figures

Options granted: 100000 shares Exercise price: $2.075 per share Underlying shares: 100000 shares +1 more

4 metrics

Options granted 100000 shares Stock options for common stock granted to director Wurth Douglas Clark

Exercise price $2.075 per share Conversion or exercise price of the granted stock options

Underlying shares 100000 shares Number of common shares underlying the granted stock options

Option expiration date 2031-08-17 Expiration date of the granted stock options

Key Terms

out-of-the-money, vest and become exercisable, point-of-care testing device

3 terms

out-of-the-money financial

"Represents out-of-the-money stock options that vest and become exercisable"

vest and become exercisable financial

"stock options that vest and become exercisable for $2.075 per share"

point-of-care testing device medical

"approval of the issuer's Symphony IL-6 point-of-care testing device"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BJDX report for Wurth Douglas Clark?

Bluejay Diagnostics (BJDX) reported that director Wurth Douglas Clark received a grant of 100,000 stock options. These options are for common stock and represent a compensation-related acquisition rather than an open-market purchase or sale.

What is the exercise price of the new BJDX stock options granted to Wurth Douglas Clark?

The stock options granted to Wurth Douglas Clark have an exercise price of $2.075 per share. They are described as out-of-the-money options that become exercisable only after vesting and upon specified FDA clearance or approval conditions.

When do Wurth Douglas Clark’s BJDX options vest and become exercisable?

The options vest and become exercisable on the first anniversary of the grant date. However, they are additionally conditioned on the U.S. FDA granting clearance or approval of Bluejay’s Symphony IL-6 point-of-care testing device.

What regulatory condition affects exercisability of Wurth Douglas Clark’s BJDX options?

The options are not exercisable unless and until the U.S. Food and Drug Administration grants clearance or approval of Bluejay Diagnostics’ Symphony IL-6 point-of-care testing device, adding a regulatory milestone condition beyond standard vesting.

When do the BJDX stock options granted to Wurth Douglas Clark expire?

The stock options granted to Wurth Douglas Clark expire on August 17, 2031. If vesting and the FDA clearance or approval condition are not satisfied before that date, any unexercised portion of the option would remain unexercisable through expiration.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/18/2026 - 04:16 PM Accepted by SEC EDGAR 08/18/2026 - 04:16 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wurth Douglas Clark

(Last)

(First)

(Middle)

C/O BLUEJAY DIAGNOSTICS, INC.

360 MASSACHUSETTS AVENUE, SUITE 203

(Street)

ACTON

MASSACHUSETTS

01720

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bluejay Diagnostics, Inc. [ BJDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$2.075	08/17/2026		A		100,000		⁽¹⁾	08/17/2031	Common Stock	100,000	$0	100,000	D

Explanation of Responses:

1. Represents out-of-the-money stock options that vest and become exercisable for $2.075 per share on the first anniversary of the grant date, provided, however, that the options shall not be exercisable unless and until the U.S. Food and Drug Administration shall have granted clearance or approval of the issuer's Symphony IL-6 point-of-care testing device.

	/s/ Douglas Clark Wurth	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR